[pubmed] Efficacy and safety of Rituximab in myasthenia gravis: A French multicentre real-life study
Posté : 12 juin 2020 12:00
Dos Santos A, et al. Eur J Neurol 2020.
ABSTRACT
INTRODUCTION: 15% of myasthenia gravis (MG) patients are refractory to conventional treatment. Case reports and a few studies show likely benefit of rituximab in these cases. Our objective was to assess the efficacy and the safety of rituximab in MG patients, in a multicentric real-life study.
METHOD: Inclusion criteria were age > 18 years old, MG with anti-Acetylcholine receptor (ACh-R) antibodies, anti-Musk antibodies or significant decrement after repetitive nerve stimulation, MG Foundation America (MGFA) score > II, refractory or steroid-dependent MG, treatment with rituximab. Efficacy was assessed at 6 months with the MGFA Post interventional score (MGFA-PIS), the Myasthenic Muscle score (MMS) and the number of patients with steroids under 10 mg/d. Adverse events were collected.
RESULTS: 29 patients were included: 20 anti-ACh-R MG, 5 anti-Musk MG and 4 seronegative MG. MGFA PIS was improved or better (Improved, Minimal Manifestations or Remission) in 86.2% of patients after 6 months of treatment (p
Source: https://pubmed.ncbi.nlm.nih.gov/3252605 ... 28&v=2.8.0